vTv Therapeutics and Reneo Pharmaceuticals Enter Licensing Agreement for PPAR-Delta Program
December 21 2017 - 4:30PM
Business Wire
vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv
Therapeutics LLC has entered into a global licensing agreement with
Reneo Pharmaceuticals, a privately-held biotechnology company
focused on developing treatments for orphan diseases. The agreement
grants Reneo Pharmaceuticals exclusive worldwide rights to
research, develop and commercialize vTv Therapeutics’ selective
peroxisome proliferator-activated receptor delta (PPAR-delta)
program. Under the terms of the agreement, vTv Therapeutics will
receive an upfront payment and will be eligible to receive future
development and commercialization milestones as well as royalties
on sales of approved products. vTv Therapeutics will also receive
shares of Reneo Pharmaceuticals' common stock.
HPP593, a functionally selective PPAR-delta agonist, has
demonstrated a lowering of low-density lipoprotein cholesterol and
triglycerides in animal models and humans, with a significant
increase in high-density lipoprotein cholesterol. HPP593 has also
demonstrated an anti-diabetic effect in several animal models of
type 2 diabetes. Phase 1 studies have shown HPP593 to be well
tolerated.
“We’re thrilled to partner with Reneo and the company’s founder
and executive chairman, Mike Grey, an established and recognized
leader in the industry, to complete the development and
commercialization of our PPAR-delta program,” said Steve Holcombe,
president and chief executive officer of vTv Therapeutics. “This
collaboration represents continued delivery on our commitment to
translate innovative science into medicine for patients, and Reneo
Pharmaceuticals' expertise makes it well suited to maximize the
potential of this candidate.”
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical
company engaged in the discovery and development of orally
administered small molecule drug candidates to fill significant
unmet medical needs. vTv has a pipeline of clinical drug candidates
led by programs for the treatment of Alzheimer’s disease and
diabetes as well as treatment of inflammatory disorders and the
prevention of muscle weakness.
Forward-Looking Statements
This release contains forward-looking statements, which involve
risks and uncertainties. These forward-looking statements can be
identified by the use of forward-looking terminology, including the
terms “anticipate,” “believe,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” “would” and, in each case, their
negative or other various or comparable terminology. All statements
other than statements of historical facts contained in this
release, including statements regarding the timing of our clinical
trials, our strategy, future operations, future financial position,
future revenue, projected costs, prospects, plans, objectives of
management and expected market growth are forward-looking
statements. These statements involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Important factors that
could cause our results to vary from expectations include those
described under the heading “Risk Factors” in our Annual Report on
Form 10-K and our other filings with the SEC. These forward-looking
statements reflect our views with respect to future events as of
the date of this release and are based on assumptions and subject
to risks and uncertainties. Given these uncertainties, you should
not place undue reliance on these forward-looking statements. These
forward-looking statements represent our estimates and assumptions
only as of the date of this release and, except as required by law,
we undertake no obligation to update or review publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise after the date of this release. We
anticipate that subsequent events and developments will cause our
views to change. Our forward-looking statements do not reflect the
potential impact of any future acquisitions, merger, dispositions,
joint ventures or investments we may undertake. We qualify all of
our forward-looking statements by these cautionary statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171221005970/en/
Investors:vTv Therapeutics Inc.Mike Biega,
617-221-9660IR@vtvtherapeutics.comorMedia:Pure CommunicationsKatie
Engleman, 910-509-3977Katie@purecommunications.com
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Aug 2024 to Sep 2024
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Sep 2023 to Sep 2024